News Corp’s Move, Inc. to Participate in Goldman Sachs Communacopia + Technology Conference

News Corp’s Move, Inc. to Participate in Goldman Sachs Communacopia + Technology Conference
News
      Corp’s
      Move,
      Inc.
      to
      Participate
      in
      Goldman
      Sachs
      Communacopia
      +
      Technology
      Conference
-

NEW YORK, September 03, 2024–(BUSINESS WIRE)–News Corp announced today that Move, Inc., operator of Realtor.com®, Chief Executive Officer Damian Eales will participate in the Goldman Sachs Communacopia + Technology Conference on Monday, September 9, 2024. The session will begin at 4:45 PM EDT (1:45 PM PDT).

To listen to the live webcast, please visit the News Corp website at https://investors.newscorp.com/calendar-events. A replay of the webcast is expected to be available at the same location for a period of time following the conference.

About News Corp
News Corp (Nasdaq: NWS, NWSA; ASX: NWS, NWSLV) is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. The company comprises businesses across a range of media, including: digital real estate services, subscription video services in Australia, news and information services and book publishing. Headquartered in New York, News Corp operates primarily in the United States, Australia, and the United Kingdom, and its content and other products and services are distributed and consumed worldwide. More information is available at: http://www.newscorp.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903582079/en/

Contacts

News Corp Investor Relations
Michael Florin
212-416-3363
[email protected]

Anthony Rudolf
212-416-3040
[email protected]

News Corp Corporate Communications
Arthur Bochner
646-422-9671
[email protected]

-

PREV Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
NEXT Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?